Physician profile
Jerod B Patchin
NPI 1386957769
$3,259.01
in general payments reported to CMS, 2019-2025
31 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $76.83 · 2022: $227 · 2023: $269 · 2024: $493 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.86 | 2019-2025 | Wegovy |
| Pfizer INC. | $340.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $270.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $218.47 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $205.74 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $188.64 | 2019-2025 | Otezla, Repatha, Evenity |
| Radius Health, INC. | $117.91 | 2019 | |
| Inspire Medical Systems, INC. | $113.68 | 2023 | Inspire |
| Urovant Sciences INC | $109.65 | 2022 | |
| Dexcom, INC. | $101.40 | 2022-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $93.46 | 2025 | |
| Abbvie INC. | $92.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.22 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $85.80 | 2019 | |
| Sumitomo Pharma America, INC. | $78.36 | 2024-2025 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.38 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $51.14 | 2025 | Eterna |
| Janssen Pharmaceuticals, INC | $48.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.23 | 2024-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $33.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2024-2025 | |
| Axsome Therapeutics, INC. | $24.91 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $24.50 | 2019 | |
| Medtronic, INC. | $23.66 | 2025 | Inceptiv |
| Otsuka America Pharmaceutical, INC. | $22.60 | 2025 | Rexulti |
| Exact Sciences Corporation | $21.63 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $17.11 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $13.74 | 2019 | |
| Genentech USA, INC. | $12.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerod Patchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.